Recent advances in liposome techniques and their applications in arthritis

Recent Patents on Biomedical Engineering

Volumn 5, Issue 1, 2012, Pages 57-62

  Park, Sang Hyug ^d,e   Seth, Aman ^a   Lee, Sangmin ^a   Min, Byoung Hyun ^e   Kim, Song Ja ^f   Song, Tongjin ^d   Hasty, Karen A ^a,b,c   Cho, Hongsik ^a,b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Campbell Clinic Memphis   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Jungwon University   (South Korea)

^e Ajou University   (South Korea)

^f Kongju National University   (South Korea)

Author keywords

Arthritis; Drug delivery; Encapsulation; Fluorescent; Immunoliposomes; Liposomes; Polyethylene glycol

Indexed keywords

ARTHRITIS; FLUORESCENT; IMMUNOLIPOSOMES; SIGNIFICANT DISCOVERY;

DIAGNOSIS; DRUG DELIVERY; ENCAPSULATION; LIPOSOMES; MEDICAL NANOTECHNOLOGY; POLYETHYLENE GLYCOLS;

PHOSPHOLIPIDS;

EID: 84860307704     PISSN: 18747647     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874764711205010057     Document Type: Review

References (34)

1. Dunlop D., Manheim L., Yelin E., Song J. and Chang R. The Cost of Arthritis. Arthritis & Rheumatism 2003; 49 (1): 101-113
2. Centers for Disease Control and Prevention: Public health and aging: projected prevalence of self-reported arthritis or chronic joint symptoms among persons aged >65 years-United States, 2005-2030. Morbidity and Mortality Weekly Report 2003, 52:489-491.
3. Dominick K., Ahern F., Gold C. and Heller D. Health-related quality of life among older adults with arthritis. Health and Quality of Life Outcomes 2004; 2:5.
4. Lawrence R., Helmick C., Arnette F., Deyo R., Felson D., Giannini E., Heyse S., Hirsch R., Hochberg M., Hunder G., Liang M., Pillemer S., Steen V., Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis and Rheumatism 1998; 41:778-799.
5. Noyori K., Jasin H. Repair characteristics of the articular cartilage surface following acute inflammatory arthritis. J Rheumatol. 1994; 21(9):1731-3.
6. Noyori K., Koshino T., Takagi T., Okamoto R., Jasin H. Binding characteristics of antitype II collagen antibody to the surface of diseased human cartilage as a probe for tissue damage. J Rheumatol. 1994; 21(2):293-6.
7. Chevalier X., Groult J., Emod J. and Planchenault T. Proteoglycandegrading activity associated with the 40kDa collagen-binding fragment of fibronectin. British Journal of Rheumatology 1996; 35: 506-514.
8. Schnyder A., Krahenbuhl S., Torok M., Drewe J. and Huwyler J. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem. J. 2004; 377: 61-67.
9. Huwyler, J., Wu, D. and Pardridge, W. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. 1993; 14164-14169.
10. Heath T., Fraley R. and Papahadjopoulos D. Antibody targeting of liposomes: cell specificity obtained by conjugation of Fab'2 to vesicle surface. Science 1980; 210:539-541.
11. Lassic, D. D. Applications of Liposomes. Liposome Handbook of Biological Physics. Liposome Technology, Inc. Elsevier Science, 1995. Chap. 10 Vol. 1.
12. Chrai S., Murari R. and Ahmad I. Liposomes (a Review) Part 2: Drug Delivery Systems. Biopharm. 2002; (Jan): 40-43.
13. Immordino M., Dosio F. and Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 2006; 1(3): 297-315.
14. Maruyama K, Takizawa T., Takahashi N., Tagawa T., Nagaike K., Iwatsuru M. Targeting efficiency of PEG-immunoliposomeconjugated antibodies at PEG terminals. Advanced Drug Delivery Reviews 1997; 24: 235-242.
15. Maruyama K. PEG-Immunoliposome. Bioscience Reports 2002; 22 (2): 251-266.
16. Cho H., Tidwell W., Aiken J., Kang M., Pinkhassik E., Rosloniec E., Stuart J., Hasty K. Use of Targeted Nanosomes to Detect Damaged Cartilage in Collagen Induced Arthritis. Podium Presentation, Orthopaedic Research Society 2011; (Paper No.0132).
17. Cho H., Tidwell W., Aiken J., Kang M., Pinkhassik E., Stuart J., Hasty K. Detection of Osteoarthritis Severity with Targeted Nanosomes. Podium Presentation, Orthopaedic Research Society 2011; (Paper No.0095).
18. Ecanow et al. Oral insulin and a method of making the same. U.S. Pat. No. 4,963,526 (1990).
19. Betageri, et al. Liposome Drug Delivery. U.S. Pat. No. 6,761,901 (2004).
20. Samad A., Sultana Y. and Aqil M. Liposomal Drug Delivery Systems: An Update Review. Current Drug Delivery 2007; 4: 297-305.
21. Payne N., Timmins P., Ambrose C. Method of preparing liposomes and products produced thereby U.S. Pat. No. 4,744,989 (1986).
22. Koning G., Schiffelers R., Wauben M., Kok R., Mastrobattista E., Molema G. Hagen T., Storm G. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphatecontaining RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum. 2006; 54(4):1198-208.
23. Kleinman D. Targeted Liposomal Therapy Shows Promise in RA Animal Models. Musculoskeletal Report: CME Publications 2006.
24. Terato K., Hasty K., Reife R., Cremer M., Kang A., Stuart J. Induction of arthritis with monoclonal antibodies to collagen. J. Immunol. 1992; 148(7): 2103-8.
25. Mayhew E. et al. Liposome Drug Delivery Method And Composition. U.S. Pat. No. 4,873,088 (1989).
26. Lau J. et al. Targeted Liposomal Drug Delivery System. U.S. Pat. No. 7,169,410 (2007).
27. Yamazaki N. et al. Therapeutic or diagnostic drug for inflammatory disease comprising targeting liposome. U.S. Pat. No. 0,286,896 (2007).
28. Katsuo A. et al. Method and Medical Agent for Diagnosis of Arthritis. U.S. Pat. No. 5,567,409 (1996).
29. Wang D., et al. Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases. U.S. Pat. No. 0311182 A1 (2009).
30. Ludwig F., et al. Nanoshells for drug delivery U.S. Pat. No. 8,048,448 (2011).
31. Venrooij W., et al. Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide U.S. Pat. No. 0,195,861 (2011).
32. Vanniasinghe A., Bender V., Manolios N. The Potential of Liposomal Drug Delivery for the Treatment of Inflammatory Arthritis. Seminars in Arthritis and Rheumatism 2009; 39: 182-196.
33. Cullis P., et al. Modified Drugs for Use in Liposomal Nanoparticles. U.S. Pat. No. 0,165,225 (2011).
34. Del Prado J. et al. Liposomal Formulation. U.S. Pat. No. 0,224,255 (2007).